Description
This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.
Amendment chain · 4 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $6,175,000 at start, $5,407,235 after amendment #3 (−$767,765).
- #02020-09-01$6,175,000
- #12021-12-13$5,937,000-$238,000
- #22022-09-20$5,407,235-$529,765
- #32023-04-04$5,407,235
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-09-01(start date) | $6,175,000 | — | This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe… |
| #1 amendment | 2021-12-13 | $5,937,000 | −$238,000 | This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe… |
| #2 amendment | 2022-09-20 | $5,407,235 | −$529,765 | This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe… |
| #3 amendment | 2023-04-04 | $5,407,235 | +$0 | This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe… |
Related records · 7
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 101328227)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2022-2023-Q4-1003639 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $4,000,000 | FY2023 |
| 172-2018-2019-Q4-919337 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $200,000 | FY2019 |
Other recipients funded under "SIF Stream 1- R&D" by Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 033-2024-2025-Q2-819558 | Coveo Solutions Inc. | FY2025 | $15,170,000 | FY2025 |
| 033-2024-2025-Q2-816194 | Kepler Communications Inc. | FY2025 | $20,000,000 | FY2025 |
| 033-2024-2025-Q2-819803 | Pratt & Whitney Canada Corporation | FY2025 | $11,322,000 | FY2025 |
| 033-2024-2025-Q1-820045 | Biotechnologies Aramis Inc. | FY2025 | $40,000,000 | FY2025 |
| 033-2023-2024-Q3-514239 | Edesa Biotech Research, Inc. | FY2024 | $23,000,000 | FY2024 |
Cite as: Glassbox record view · Federal grants & contributions · 033-2020-2021-Q3-513415 · retrieved 2026-11-16.